Navigation Links
Multi Merci Trial Results Published in Peer Reviewed Journal
Date:3/6/2008

MOUNTAIN VIEW, Calif., March 6 /PRNewswire/ -- Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced that the results of its Multi MERCI trial will be published in the April 2008 edition of the medical journal, Stroke. The Multi MERCI trial was the second trial studying safety and efficacy of the Merci Retrieval System(TM), a "corkscrew-type" device that is delivered into the brain and is designed to restore blood flow by engaging, capturing and removing blood clots that cause ischemic stroke. The full, peer reviewed trial results are available now to online subscribers. Stroke is published by the American Heart Association.

In the Multi MERCI trial, patients treated with the newer Merci(R) L5 Retriever had their cerebral blood flow successfully restored 57.3% of the time with the Merci Retrieval System alone. With the addition of adjunctive therapy, physicians successfully restored cerebral blood flow 69.5% of the time. For patients to be successfully revascularized, not only the target vessel, but all treatable downstream vessels needed to achieve TIMI 2 or 3 flow.

In addition, a total of 36% of all patients treated achieved a "good" outcome at 90 days post procedure, a higher rate than reported in any other device trial in large vessel acute ischemic stroke patients. Ninety-day clinical outcomes in stroke trials are generally measured using the modified Rankin Score, a measure of functional independence, with a score of 2 or less considered a good outcome. These outcome data are superior to those reported in recent studies of other devices in which successful revascularization was not as stringently defined.

Multi MERCI was a multi-center, prospective trial including 164 patients treated at 15 hospitals in the United States and Canada. All patients had moderate-to-severe, large vessel ischemic strokes. The trial included patients who were ineligible for or had failed treatment with a clotdissolving drug called t-PA. Patients had treatment initiated up to eight hours after stroke symptom onset, extending the three-hour treatment window for intravenous clot-dissolving drugs.

"We are excited that both clinical outcome and recanalization rates are improved with the next-generation devices tested in the Multi MERCI Trial. This provides further evidence that timely recanalization is a surrogate marker for clinical benefit, especially when one uses the conservative definition of recanalization used in this trial," said Wade Smith, MD, PhD Professor of Neurology at the University of California, San Francisco, and Principal Investigator for the Multi MERCI trial.

About Concentric Medical

Concentric Medical is located in Mountain View, California, and was founded in August 1999. The company manufactures and markets the Merci Retrieval System, which is available in over 250 leading stroke centers around the world. Concentric Medical estimates that over 7,000 patients have been treated with its devices. For more information about Concentric Medical, please visit http://www.concentric-medical.com.

Media Contact:

Andrew Gordon

650-810-1701

agordon@concentric-medical.com


'/>"/>
SOURCE Concentric Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
2. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
3. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
4. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
5. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
6. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
7. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
8. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
9. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... -- Exactly 50 years ago today, the Monterey Pop Festival opened ... the San Francisco "Summer of Love."  To celebrate the anniversary, ... in strategic market research portals that it will begin delivering ... Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, Embodied ... Startups pitch competition and came away with $25,000 ... is described by Forbes as "entering the life of ... Association as teaching "empathy to medical professionals in an ... was recently named a finalist for the Department of ...
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
Breaking Medicine Technology:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... London UK (PRWEB) , ... June 27, 2017 , ... ... a clinical study is whether they can trust the sponsor to pay them correctly ... vital that sponsors and CROs establish payment strategies that encourage sites to work on ...
(Date:6/27/2017)... ... , ... The Congressional Budget Office (CBO) projects that the Better Care Reconciliation ... and Affordable Care Act (ACA), would result in 22 million Americans losing their health ... More than 20 million Americans have gained health insurance under the ACA, and from ...
(Date:6/27/2017)... ... 27, 2017 , ... A January 18th article on medGadget reports ... billion by the year 2024 according to a new report. The article also notes ... from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says ...
(Date:6/27/2017)... New York, NY (PRWEB) , ... June 27, ... ... communications and marketing experts to contribute to an upcoming case studies guidebook. This ... or her organization. , This book will include articles, case studies and how-to’s ...
Breaking Medicine News(10 mins):